A systematic review on parental vaccine hesitancy for childhood immunizations in the European region: Can findings be generalized?

Hum Vaccin ImmunotherJun 5, 2026 (epub)
Clinical ResearchPreventive Medicine / Public HealthPediatricsOpen access

Toon Janssen, Julie Degraeve, Ilse De Coster et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined parental vaccine hesitancy (VH) for childhood immunizations across Europe, analyzing 49 articles published from 2015 to 2024. It found that trust in healthcare professionals significantly influences vaccination decisions, while fear of side effects and logistical barriers deter parents. The study highlights the need for tailored strategies to address VH in different contexts.

Key findings

  • Trust in healthcare professionals is a key factor influencing parental vaccine hesitancy.
  • Fear of side effects and logistical barriers negatively impact vaccination decisions.
  • Demographic determinants of vaccine hesitancy are not generalizable across European countries.
  • Tailored, country-specific strategies are essential for addressing vaccine hesitancy effectively.

Why it matters

Understanding the factors influencing vaccine hesitancy is crucial for developing effective public health strategies. Tailored approaches can enhance trust and address barriers, ultimately improving childhood vaccination rates and public health outcomes.

Source

PubMed · PMID 42246489Free full text on PubMed Central

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Preventive Medicine / Public Health

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.